G169R mutation diminishes the metabolic activity of CYP2D6 in Chinese

Drug Metabolism and Disposition

Volumn 27, Issue 3, 1999, Pages 385-388

  Wang, Su Lan ^a   Lai, Ming Derg ^a   Huang, Jin Ding ^a,b  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ADENINE; BUFURALOL; COMPLEMENTARY DNA; CYTOSINE; DEBRISOQUINE; DEBRISOQUINE 4 HYDROXYLASE; GUANINE; NUCLEOTIDE; THYMINE;

ACETYLATOR PHENOTYPE; ALLELE; ANIMAL CELL; ARTICLE; CHINESE; CONTROLLED STUDY; DNA SEQUENCE; DRUG HYDROXYLATION; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC POLYMORPHISM; HAPLOTYPE; HUMAN; LIVER MICROSOME; MAJOR CLINICAL STUDY; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RAT; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SITE DIRECTED MUTAGENESIS;

ANIMALIA;

EID: 0032963135     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (11)

1. Bertilsson L, Lou YQ, Du YL, Liu Y, Kuang TY, Liao XM, Wang KY, Reviriego J, Islius L and Sjöqvist F (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397.
2. Broly F, Marez D, Sabbagh N, Legrand M, Boone P and Meyer UA (1995) An efficient strategy for detection of known and new mutations of the CYP2D6 gene using single strand conformation polymorphism analysis. Pharmacogenetics 5:373-384.
3. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE, Gonzalez FJ, Huang JD, Idle JR, Ingelman-Sundberg M, Ishizaki T, Jacqz-Aigrain E, Meyer UA, Nebert DW, Steen VM, Wolf CR and Zanger UM (1996) Nomenclature for human CYP2D6 alleles. Pharmacogenetics 6:193-201.
4. Johansson I, Oscarson M, Yue QY, Bertilsson L, Sjöqvist F and Ingelman-Sundberg M (1994) Genetic analysis of the Chinese cytochrome P450 2D locus. Characterization of variant CYP2D6 genes present in subjects with diminished capacity for debrisoquine hydroxylation. Mol Pharmacol 46:452-459.
5. Kagimoto M, Heim M, Kagimoto K, Zeugin T and Meyer UA (1990) Multiple mutations of the human cytochrome P450IID6 gene (CYP2D6) in poor metabolizers of debrisoquine. J Biol Chem 265:17209-17214.
6. Lai ML, Wang SL, Lai MD, Lin ET, Tse M and Huang JD (1995) Propranolol disposition in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 58:264-268.
7. Marez D, Legrand M, Sabbagh N, Lo Guidice JM, Spire C, Lafitte JJ, Meyer UA and Broly F (1997) Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: Characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7:193-202.
8. Matsunaga E, Zeugin T, Zanger UM, Aoyama T, Meyer UA and Gonzalez FJ (1990) Sequence requirements for cytochrome P-450IID1 catalytic activity. J Biol Chem 265:17197-17201.
9. Tseng CY, Wang SL, Lai MD, Lai ML and Huang JD (1996) Formation of morphine from codeine in Chinese subjects of different CYP2D6 genotypes. Clin Pharmacol Ther 60:177-182.
10. Wang SL, Huang JD, Lai MD, Liu BH and Lai ML (1993) Molecular basis of genetic variation in debrisoquin hydroxylation in Chinese subjects. Polymorphism in RFLP and DNA sequence of CYP2D6. Clin Pharmacol Ther 53:410-418.
11. Wang SL, Lai MD, Lai ML and Huang JD (1995) R296C and other CYP2D6 mutations in Chinese. Pharmacogenetics 5:385-388.